Prostate cancer (advanced, hormone dependent) - degarelix depot [ID590]

Anticipated publication date:

Degarelix depot for treating advanced hormone dependent prostate cancer
 
Status
In development
Anticipated publication date
May 2014
Process
STA

Provisional Schedule

Closing date for invited submissions / evidence submission: 29 August 2013
1st appraisal committee meeting: 27 November 2013
2nd appraisal committee meeting 11 February 2014

Project Team

Technical Lead: Pilar Pinilla-Dominguez
Communications manager: Alice Law
Project manager:

Kate Moore

Consultees

Manufacturers/sponsors
  • Ferring Pharmaceuticals (degarelix)
Patient/carer groups
  • Prostate Cancer Support Federation
  • Prostate Cancer UK
Professional groups
  • British Association of Urological Surgeons
  • British Uro-Oncology Group
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Physicians
  • Urology Foundation
Others
  • Department of Health
  • NHS Durham Dales, Easington and Sedgefield CCG
  • NHS England
  • NHS Southport and Formby CCG
  • Welsh Government

Commentators

General
  • Department of Health,Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
Comparator manufacturers
  • Accord Healthcare (bicalutamide) (Confidentiality agreement not signed, not participating)
  • AstraZeneca (bicalutamide, goserelin)
  • Bayer (cyproterone)
  • Bluefish Pharmaceuticals (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Ferring Pharmaceticals (triptorelin)
  • Genus Pharmaceuticals (goserelin) (Confidentiality agreement not signed, not participating)
  • Glenmark Generics Europe (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Ipsen (triptorelin)
  • Medac (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Neolab (cyproterone) (Confidentiality agreement not signed, not participating)
  • Orion Pharma UK (histrelin)
  • Sanofi (buserelin)
  • Takeda UK (leuprorelin) (Confidentiality agreement not signed, not participating)
  • Teva UK (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Wockhardt UK (cyproterone) (Confidentiality agreement not signed, not participating)
  • Zentiva (bicalutamide) (Confidentiality agreement not signed, not participating)
Relevant research groups
  • National Cancer Research Network
Evidence Review Group
  • School of Health and Related Research (ScHARR)
  • National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
  • National Collaborating Centre for Cancer
Associated Public Health Groups
  • None
Get involved